Mostrando postagens com marcador PTSD. Mostrar todas as postagens
Mostrando postagens com marcador PTSD. Mostrar todas as postagens

sábado, 9 de maio de 2015

PTSD linked to accelerated aging

 

Fri, 05/08/2015

Scott LaFee, University of California, San Diego

Human chromosomes are shown in blue, with telomeres appearing as yellow pinpoints. Image: National Institutes of Health

Human chromosomes are shown in blue, with telomeres appearing as yellow pinpoints. Image: National Institutes of HealthIn recent years, public health concerns about post-traumatic stress disorder (PTSD) have risen significantly, driven in part by affected military veterans returning from conflicts in the Middle East and elsewhere. PTSD is associated with number of psychological maladies, among them chronic depression, anger, insomnia, eating disorders and substance abuse.

Writing in the American Journal of Geriatric Psychiatry, researchers at Univ. of California, San Diego School of Medicine and Veterans Affairs San Diego Healthcare System suggest that people with PTSD may also be at risk for accelerated aging or premature senescence.

"This is the first study of its type to link PTSD, a psychological disorder with no established genetic basis, which is caused by external, traumatic stress, with long-term, systemic effects on a basic biological process such as aging," said Dilip V. Jeste, MD, Distinguished Professor of Psychiatry and Neurosciences and director of the Center on Healthy Aging and Senior Care at UC San Diego, who is the senior author of this study.

Researchers had previously noted a potential association between psychiatric conditions, such as schizophrenia and bipolar disorder, and acceleration of the aging process. Jeste and colleagues determined to see if PTSD might show a similar association by conducting a comprehensive review of published empirical studies relevant to early aging in PTSD, covering multiple databases going back to 2000.

There is no standardized definition of what constitutes premature or accelerated senescence. For guidance, the researchers looked at early aging phenomena associated with non-psychiatric conditions, such as Hutchinson-Gilford progeria syndrome, HIV infection and Down's syndrome. The majority of evidence fell into three categories: biological indicators or biomarkers, such as leukocyte telomere length (LTL), earlier occurrence or higher prevalence of medical conditions associated with advanced age and premature mortality.

In their literature review, the UC San Diego team identified 64 relevant studies; 22 were suitable for calculating overall effect sizes for biomarkers, 10 for mortality.

All six studies looking specifically at LTL found reduced telomere length in persons with PTSD. Leukocytes are white blood cells. Telomeres are stretches of protective, repetitive nucleotide sequences at the ends of chromosomes. These sequences shorten with every cell replication and are considered a strong measure of the aging process in cells.

The scientists also found consistent evidence of increased pro-inflammatory markers, such as C-reactive protein and tumor necrosis factor alpha, associated with PTSD.

A majority of reviewed studies found increased medical comorbidity of PTSD with several targeted conditions associated with normal aging, including cardiovascular disease, type 2 diabetes, gastrointestinal ulcer disease and dementia.

Seven of 10 studies indicated a mild-to-moderate association of PTSD with earlier mortality, consistent with an early onset or acceleration of aging in PTSD.

"These findings do not speak to whether accelerated aging is specific to PTSD, but they do argue the need to re-conceptualize PTSD as something more than a mental illness," said first author James B. Lohr, MD, professor of psychiatry. "Early senescence, increased medical morbidity and premature mortality in PTSD have implications in health care beyond simply treating PTSD symptoms. Our findings warrant a deeper look at this phenomenon and a more integrated medical-psychiatric approach to their care."

Barton Palmer, PhD, professor of psychiatry and a coauthor of the study, cautioned that "prospective longitudinal studies are needed to directly demonstrate accelerated aging in PTSD and to establish underlying mechanisms."

Source: University. of California, San Diego

segunda-feira, 13 de outubro de 2014

Common anesthetic procedure dramatically improves well being of veterans with PTSD

 


A single application of a common anesthetic procedure could be the answer to alleviating anxiety, depression and psychological pain in those suffering from chronic, extreme post-traumatic stress disorder (PTSD).

In a study presented at the ANESTHESIOLOGY™ 2014 annual meeting, researchers followed 12 patients with PTSD who had undergone a simple anesthetic procedure called a stellate ganglion block (SGB). This common procedure involves injecting a small amount of local anesthesia into the base of the neck. SGB is traditionally used to treat a variety of conditions, from pain syndromes to sleep disorders.

"While it doesn't cure the problem, we found that SGB appears to be a fast-acting and effective long-term treatment for chronic, extreme PTSD in veterans," said Michael T. Alkire, M.D., staff anesthesiologist at the Long Beach VA Healthcare System in California. "These improvements far outlasted what we would expect from SGB, which is usually used as a temporary nerve block and typically lasts three to five hours."

In the study, the patients each were given one SGB and followed closely with structured interviews and other psychological tests for six months after treatment. The positive effects of the SGB were evident often within minutes and resulted in significant improvement of scores for the Clinician Administered PTSD Score, or CAPS, the test used to measure the severity of PTSD.

Symptoms improved over time, and after one month, CAPS scores registered normal to mild PTSD levels for most of the patients. Positive effects were still seen at three months, but began fading and were generally gone by six months. Overall, 75 percent of the participants reported significant improvement of their PTSD symptoms after the SGB.

Data from the study further suggested that SGB might also be an effective initial treatment for depression and anxiety disorders.

"Further work is needed to identify which patients might respond best to this treatment as well as understand the mechanisms involved that produce such a rapid, dramatic and long-term change in psychological health for some patients," said Dr. Alkire, who also is a professor of anesthesiology at the University of California-Irvine.


Story Source:

The above story is based on materials provided by American Society of Anesthesiologists (ASA). Note: Materials may be edited for content and length.